Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer

Journal of Opioid Management

Volumn 6, Issue 3, 2010, Pages 181-191

  Slatkin, Neal E ^a   Rhiner, Michelle I ^b   Gould, Errol M ^c   Ma, Tina ^c   Ahdieh, Harry ^c  

^a California Cancer Specialists Medical Group   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Cancer; Cancer pain; Chronic pain; Extension trial; Opioid; Oxymorphone

Indexed keywords

OXYMORPHONE;

ADULT; AGED; AMNESIA; ARTICLE; CANCER PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEDATION; SIDE EFFECT; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OXYMORPHONE; PAIN, INTRACTABLE;

EID: 77954604023     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2010.0016     Document Type: Article

References (33)

1. Goudas LC, Bloch R, Gialeli-Goudas M, et al.: The epidemiology of cancer pain. Cancer Invest. 2005; 23(2): 182-190.
2. Mao JJ, Armstrong K, Bowman MA, et al.: Symptom burden among cancer survivors: Impact of age and comorbidity. J Am Board Fam Med. 2007; 20(5): 434-443.
3. Peng WL, Wu GJ, Sun WZ, et al.: Multidisciplinary management of cancer pain: A longitudinal retrospective study on a cohort of end-stage cancer patients. J Pain Symptom Manage. 2006; 32(5): 444-452.
4. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al.: Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Ann Oncol. 2007; 18(9): 1437-1449. (Pubitemid 47365475)
5. Mercadante S, Roila F, Berretto O, et al.: Prevalence and treatment of cancer pain in Italian oncological wards centres: A cross-sectional survey. Support Care Cancer. 2008; 16(11): 1203-1211.
6. Russell PB, Aveyard SC, Oxenham DR: An assessment of methods used to evaluate the adequacy of cancer pain management. J Pain Symptom Manage. 2006; 32(6): 581-588.
7. Macdonald L, Bruce J, Scott NW, et al.: Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005; 92(2): 225-230.
8. Johnson VM, Teno JM, Bourbonniere M, et al.: Palliative care needs of cancer patients in U.S. nursing homes. J Palliat Med. 2005; 8(2): 273-279.
9. Rolnick SJ, Jackson J, Nelson WW, et al.: Pain management in the last six months of life among women who died of ovarian cancer. J Pain Symptom Manage. 2007; 33(1): 24-31.
10. Deandrea S, Montanari M, Moja L, et al.: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008; 19(12): 1985-1991.
11. Swarm R, Anghelescu DL, Benedetti C, et al.: Adult cancer pain. J Natl Compr Canc Netw. 2007; 5(8): 726-751.
12. World Health Organization: Cancer Pain Relief. Geneva, Switzerland: WHO Office of Publication, 1996.
13. Zech DF, Grond S, Lynch J, et al.: Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain. 1995; 63(1): 65-76.
14. Miaskowski C, Cleary J, Burney R, et al.: Guideline for the Management of Cancer Pain in Adults and Children. Glenview, IL: American Pain Society, 2005.
15. Cherny NJ, Chang V, Frager G, et al.: Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995; 76(7): 1283-1293.
16. Riley J, Ross JR, Rutter D, et al.: No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006; 14(1): 56-64. (Pubitemid 43119598)
17. Slatkin NE: Opioid switching and rotation in primary care: Implementation and clinical utility. Curr Med Res Opin. 2009; 25(9): 2133-2150.
18. Coluzzi PH, Schwartzberg L, Conroy JD, et al.: Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001; 91(1-2): 123-130.
19. Beaver WT, Wallenstein SL, Houde RW, et al.: Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol. 1977; 17(4): 186-198.
20. Metzger TG, Paterlini MG, Ferguson DM, et al.: Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: Exploring the "address" recognition locus. J Med Chem. 2001; 44(6): 857-862.
21. Adams MP, Ahdieh H: Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study. Pharmacotherapy. 2004; 24(4): 468-476.
22. Hale ME, Ahdieh H, Ma T, et al.: Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007; 8(2): 175-184.
23. Katz N, Rauck R, Ahdieh H, et al.: A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007; 23(1): 117-128.
24. McIlwain H, Ahdieh H: Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study. Am J Ther. 2005; 12(2): 106-112.
25. Gabrail NY, Dvergsten C, Ahdieh H: Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Curr Med Res Opin. 2004; 20(6): 911-918.
26. Sloan P, Slatkin N, Ahdieh H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer. 2005; 13(1): 57-65.
27. Eisenberg E, McNicol ED, Carr DB: Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA. 2005; 293(24): 3043-3052.
28. Rauck R, Ma T, Kerwin R, et al.: Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain. Pain Med. 2008; 9(7): 777-785.
29. Citron ML, Kaplan R, Parris WC, et al.: Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. Cancer Invest. 1998; 16(8): 562-571. (Pubitemid 28541776)
30. Likar R, Kayser H, Sittl R: Long-term management of chronic pain with transdermal buprenorphine: A multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther. 2006; 28(6): 943-952.
31. Wallace M, Moulin DE, Rauck RL, et al.: Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag. 2009; 5(2): 97-105.
32. Hanna M, Tuca A, Thipphawong J: An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain. BMC Palliat Care. 2009; 8: 14.
33. Muriel C, Failde I, Mico JA, et al.: Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: A multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther. 2005; 27(4): 451-462.